The future R&D landscape in non-alcoholic steatohepatitis (NASH)

•There is an unmet need for new therapies to treat NASH.•New therapies will have different modes of action, aligned to the stage of disease.•They must have additive benefit, in combination with emerging standards of care.•New biomarkers and pre-clinical models will facilitate drug research and devel...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Drug discovery today 2019-02, Vol.24 (2), p.560-566
Hauptverfasser:	Black, Darcey, Brockbank, Sarah, Cruwys, Simon, Goldenstein, Kim, Hein, Peter, Humphries, Bob
Format:	Artikel
Sprache:	eng
Schlagworte:	Biomarkers Biomedical Research Drug Development Drug Therapy, Combination Humans Non-alcoholic Fatty Liver Disease - drug therapy
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!